Clinical Trials
2 trialsNCT06558773 2026-02-11
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Chinese PLA General Hospital
Phase 2 Recruiting
NCT07138547 2026-01-02
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
Chinese PLA General Hospital
Phase 1/2 Recruiting